Amy G Feldman1, Ronald J Sokol2, Regina M Hardison3, Estella M Alonso4, Robert H Squires5, Michael R Narkewicz2. 1. Digestive Health Institute, Children's Hospital Colorado, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. Electronic address: amy.feldman@childrenscolorado.org. 2. Digestive Health Institute, Children's Hospital Colorado, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. 3. Epidemiology Data Center Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. 4. Division of Gastroenterology, Hepatology and Nutrition, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL. 5. Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
OBJECTIVES: To assess the accuracy of blood lactate and lactate: pyruvate molar ratio (L:P) as a screen for mitochondrial, respiratory chain, or fatty acid oxidation disorders in children with pediatric acute liver failure (PALF); to determine whether serum lactate ≥ 2.5 mmol/L or L:P ≥ 25 correlated with biochemical variables of clinical severity; and to determine whether lactate or L:P is associated with clinical outcome at 21 days. STUDY DESIGN: Retrospective review of demographic, clinical, laboratory, and outcome data for PALF study group participants who had lactate and pyruvate levels collected on the same day. RESULTS: Of 986 participants, 110 had lactate and pyruvate levels collected on the same day. Of the 110, the etiology of PALF was a mitochondrial disorder in 8 (7%), indeterminate in 65 (59%), and an alternative diagnosis in 37 (34%). Lactate, pyruvate, and L:P were similar among the 3 etiologic groups. There was no significant association between the initial lactate or L:P and biochemical variables of clinical severity or clinical outcome at 21 days. CONCLUSIONS: A serum lactate ≥ 2.5 mmol/L and/or elevated L:P was common in all causes of PALF, not limited to those with a mitochondrial etiology, and did not predict 21-day clinical outcome. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00986648.
OBJECTIVES: To assess the accuracy of blood lactate and lactate: pyruvate molar ratio (L:P) as a screen for mitochondrial, respiratory chain, or fatty acidoxidation disorders in children with pediatric acute liver failure (PALF); to determine whether serum lactate ≥ 2.5 mmol/L or L:P ≥ 25 correlated with biochemical variables of clinical severity; and to determine whether lactate or L:P is associated with clinical outcome at 21 days. STUDY DESIGN: Retrospective review of demographic, clinical, laboratory, and outcome data for PALF study group participants who had lactate and pyruvatelevels collected on the same day. RESULTS: Of 986 participants, 110 had lactate and pyruvatelevels collected on the same day. Of the 110, the etiology of PALF was a mitochondrial disorder in 8 (7%), indeterminate in 65 (59%), and an alternative diagnosis in 37 (34%). Lactate, pyruvate, and L:P were similar among the 3 etiologic groups. There was no significant association between the initiallactate or L:P and biochemical variables of clinical severity or clinical outcome at 21 days. CONCLUSIONS: A serum lactate ≥ 2.5 mmol/L and/or elevated L:P was common in all causes of PALF, not limited to those with a mitochondrial etiology, and did not predict 21-day clinical outcome. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00986648.
Authors: Sarah E Calvo; Alison G Compton; Steven G Hershman; Sze Chern Lim; Daniel S Lieber; Elena J Tucker; Adrienne Laskowski; Caterina Garone; Shangtao Liu; David B Jaffe; John Christodoulou; Janice M Fletcher; Damien L Bruno; Jack Goldblatt; Salvatore Dimauro; David R Thorburn; Vamsi K Mootha Journal: Sci Transl Med Date: 2012-01-25 Impact factor: 17.956
Authors: Robert H Squires; Benjamin L Shneider; John Bucuvalas; Estella Alonso; Ronald J Sokol; Michael R Narkewicz; Anil Dhawan; Philip Rosenthal; Norberto Rodriguez-Baez; Karen F Murray; Simon Horslen; Martin G Martin; M James Lopez; Humberto Soriano; Brendan M McGuire; Maureen M Jonas; Nada Yazigi; Ross W Shepherd; Kathleen Schwarz; Steven Lobritto; Daniel W Thomas; Joel E Lavine; Saul Karpen; Vicky Ng; Deirdre Kelly; Nancy Simonds; Linda S Hynan Journal: J Pediatr Date: 2006-05 Impact factor: 4.406
Authors: François-Guillaume Debray; Grant A Mitchell; Pierre Allard; Brian H Robinson; James A Hanley; Marie Lambert Journal: Clin Chem Date: 2007-03-23 Impact factor: 8.327
Authors: Richard H Haas; Sumit Parikh; Marni J Falk; Russell P Saneto; Nicole I Wolf; Niklas Darin; Lee-Jun Wong; Bruce H Cohen; Robert K Naviaux Journal: Mol Genet Metab Date: 2008-02-01 Impact factor: 4.797
Authors: Michael R Narkewicz; Simon Horslen; Regina M Hardison; Benjamin L Shneider; Norberto Rodriguez-Baez; Estella M Alonso; Vicky L Ng; Mike A Leonis; Kathleen M Loomes; David A Rudnick; Philip Rosenthal; Rene Romero; Girish C Subbarao; Ruosha Li; Steven H Belle; Robert H Squires Journal: Clin Gastroenterol Hepatol Date: 2018-04-30 Impact factor: 11.382
Authors: Borja Herrero de la Parte; Mireia Irazola; Jorge Pérez-Muñoz; Irati Rodrigo; Sira Iturrizaga Correcher; Carmen Mar Medina; Kepa Castro; Nestor Etxebarria; Fernando Plazaola; Jose Ángel García; Ignacio García-Alonso; Jose Javier Echevarría-Uraga Journal: Nanomaterials (Basel) Date: 2021-05-17 Impact factor: 5.076